Research Analysts Issue Forecasts for Zeltiq Aesthetics Inc.’s FY2016 Earnings (ZLTQ)
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) – Equities research analysts at William Blair increased their FY2016 earnings per share estimates for Zeltiq Aesthetics in a research note issued to investors on Thursday. William Blair analyst M. Kaczor now forecasts that the brokerage will earn ($0.01) per share for the year, up from their prior estimate of ($0.11). William Blair also issued estimates for Zeltiq Aesthetics’ Q1 2017 earnings at ($0.21) EPS, Q2 2017 earnings at ($0.08) EPS and Q3 2017 earnings at $0.19 EPS.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last released its quarterly earnings data on Wednesday, November 9th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.04. Zeltiq Aesthetics had a negative return on equity of 6.45% and a net margin of 9.48%. The business had revenue of $95.20 million for the quarter, compared to the consensus estimate of $90.84 million. During the same quarter in the previous year, the company posted $0.05 EPS. The company’s revenue was up 55.6% compared to the same quarter last year.
A number of other research analysts have also weighed in on the company. Zacks Investment Research lowered Zeltiq Aesthetics from a “strong-buy” rating to a “hold” rating in a report on Saturday. Northcoast Research reaffirmed a “buy” rating on shares of Zeltiq Aesthetics in a report on Tuesday, November 8th. Canaccord Genuity raised their target price on Zeltiq Aesthetics from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, November 10th. Brean Capital reaffirmed a “buy” rating on shares of Zeltiq Aesthetics in a report on Monday, October 24th. Finally, Stifel Nicolaus raised their target price on Zeltiq Aesthetics from $38.00 to $52.00 and gave the stock a “buy” rating in a report on Wednesday, September 21st. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $42.78.
Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 40.38 on Monday. Zeltiq Aesthetics has a 1-year low of $18.41 and a 1-year high of $41.48. The company has a market cap of $1.61 billion, a P/E ratio of 52.10 and a beta of 0.89. The firm has a 50-day moving average price of $37.67 and a 200-day moving average price of $33.57.
In other news, VP Bradley Hauser sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $37.33, for a total value of $111,990.00. Following the transaction, the vice president now owns 46,240 shares in the company, valued at $1,726,139.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark J. Foley sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 13th. The shares were sold at an average price of $40.55, for a total value of $405,500.00. Following the completion of the transaction, the insider now owns 281,941 shares in the company, valued at approximately $11,432,707.55. The disclosure for this sale can be found here. 15.60% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Credit Suisse AG increased its position in Zeltiq Aesthetics by 500.1% in the third quarter. Credit Suisse AG now owns 228,645 shares of the company’s stock valued at $8,968,000 after buying an additional 190,545 shares during the period. Symmetry Peak Management LLC purchased a new position in Zeltiq Aesthetics during the third quarter valued at $294,000. D. E. Shaw & Co. Inc. increased its position in Zeltiq Aesthetics by 102.2% in the third quarter. D. E. Shaw & Co. Inc. now owns 54,507 shares of the company’s stock valued at $2,138,000 after buying an additional 27,551 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Zeltiq Aesthetics during the third quarter valued at $945,000. Finally, Two Sigma Advisers LP purchased a new position in Zeltiq Aesthetics during the third quarter valued at $1,664,000.
About Zeltiq Aesthetics
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.